A Study to Evaluate Vimseltinib in Adults With Active Chronic Graft-Versus-Host Disease (cGVHD) (NCT06619561)
A Phase 2, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, PK, and Efficacy of Vimseltinib in Adults With Active Chronic GVHD After Failure of Prior Systemic Therapy
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to determine if vimseltinib is safe, tolerable and works effectively to treat adults with active moderate to severe cGVHD. Participants will be treated with vimseltinib in 28-day treatment cycles for approximately 2 years.
Who can join: Review the eligibility criteria below.
Location: City of Hope National Medical Center — Duarte, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (26 Sites)
Showing the first 25 of 26 sites.
- City of Hope National Medical Center — Duarte, California
- Ronald Regan UCLA Medical Center — Los Angeles, California
- University of California Irvine Health — Orange, California
- AdventHealth Orlando — Orlando, Florida
- Moffitt Cancer Center — Tampa, Florida
- Emory University Winship Cancer Institute — Atlanta, Georgia
- University of Illinois Medical Center - Hematology & Oncology — Chicago, Illinois
- University of Kansas Cancer Center-Westwood — Westwood, Kansas
- University of Kentucky Markey Cancer Center — Lexington, Kentucky
- Dana-Farber Cancer Institute — Boston, Massachusetts
- Henry Ford Cancer Institute — Detroit, Michigan
- Washington University School of Medicine - Siteman Cancer Center — St Louis, Missouri
- Levine Cancer Institute — Charlotte, North Carolina
- Duke University Hospital — Durham, North Carolina
- Oncology Hematology Care Clinical Trials, LLC — Cincinnati, Ohio
- Cleveland Clinic — Cleveland, Ohio
- The Ohio State University Comprehensive Cancer Center — Columbus, Ohio
- Oregon Health and Science University — Portland, Oregon
- UPMC Hillman Cancer Center — Pittsburgh, Pennsylvania
- Avera Cancer Institute — Sioux Falls, South Dakota
- Tristar Bone Marrow Transplant — Nashville, Tennessee
- Vanderbilt-Ingram Cancer Center — Nashville, Tennessee
- St. David's South Austin Medical Center — Austin, Texas
- UT Southwestern Medical Center — Dallas, Texas
- Intermountain Health — Salt Lake City, Utah
📞 Contact the Study Coordinator
Phone: (888) 724-3274
Email: clinicaltrials@deciphera.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Chronic Graft-Versus-Host Disease (cGVHD)
Explore by condition: All Chronic Graft-Versus-Host Disease (cGVHD) clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.